Skip to content

    Recently Viewed


      Home /
      Lung Cancer Initiative

      Lung Cancer Initiative

      Lung cancer is the leading cause of cancer deaths globally, and it is often detected too late, with more than half of cases metastasizing by the time they are first diagnosed … but there is hope.

      With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.
      As an R&D engine, the LCI takes a multidisciplinary approach in bringing together the unparalleled expertise, technology, scale and reach across Johnson & Johnson within its Pharmaceutical, Medical Device and Consumer Health sectors, and works with collaborators worldwide to advance innovations that aim to create more effective and personalized treatments for lung cancer with the goal to improve patient outcomes.


      • Headshot of Avi Spira

        Avi Spira, M.D.,

        MScGlobal Head, LCI
      • Circular headshot of Silvia Chen, Ph.D., MBA

        Silvia Chen, Ph.D., MBA

        Head of China, LCI and WWDA
      • Circular crop of headshot of Hannah McEwen, Ph.D.

        Hannah McEwen, Ph.D.

        Head of Engineering Sciences, LCI
      • Michael Morrissey

        Michael Morrissey, Ph.D.

        Global Head, Early Detection & Data Science, LCI and WWDA
      • Circular crop of headshot of Tina Soares

        Tina Soares

        Vice President, LCI & WWDA Scientific & Clinical Operations
      • Phillippe Szapary

        Philippe Szapary, M.D., MSCE

        Head of Clinical Development, LCI

      Featured stories & discussions

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.